Read by QxMD icon Read


Benilde Cosmi
Idiopathic or unprovoked venous thromboembolism is an event occurring in the absence of any apparent provoking or triggering environmental risk factors, such as surgery, trauma, and immobilization. Areas covered: Unprovoked VTE can be associated with occult cancer, but only limited, and not extensive cancer screening, may be warranted, as the rate of occult cancer is low in such patients. Routine thrombophilia testing is not currently recommended as it does not influence the management of the disease. The duration of anticoagulation for unprovoked VTE after the first three months is still debated as the disease tends to recur regardless of treatment duration...
October 14, 2016: Expert Review of Cardiovascular Therapy
Jeanine M Walenga, Jawed Fareed, Eduardo Ramacciotti
No abstract text is available yet for this article.
December 2016: International Angiology: a Journal of the International Union of Angiology
Daniela Ligi, Giovanni Mosti, Lidia Croce, Joseph D Raffetto, Ferdinando Mannello
Venous leg ulcers (VLUs) produce wound fluid (WF), as a result of inflammatory processes within the wound. It is unclear if WF from different healing phases of VLU has a peculiar biochemical profile and how VLU microenvironment affects the wound healing mechanisms. This study was conducted to evaluate the cytokine/chemokine profiles in WF from distinct VLU phases, in WF- and LPS-stimulated monocytes and treated with glycosaminoglycan Sulodexide, a therapeutic option for VLU healing. WF and plasma were collected from patients with VLU during active inflammatory (Infl) and granulating (Gran) phases...
October 2016: Biochimica et Biophysica Acta
Daniela Ligi, Giovanni Mosti, Lidia Croce, Joseph D Raffetto, Ferdinando Mannello
Venous leg ulcers (VLU) are characterized by sustained proteolytic microenvironment impairing the healing process. Wound fluid (WF) reflect the biomolecular activities occurring within the wound area; however, it is unclear if WF from different healing phases have different proteolytic profiles and how VLU microenvironment affects the wound healing mechanisms. We investigated the proteolytic network of WF from distinct VLU phases, and in WF- and LPS-stimulated THP-1 monocytes treated with glycosaminoglycan sulodexide, a well known therapeutic approach for VLU healing...
October 2016: Biochimica et Biophysica Acta
P Gamba, M Pavia
OBJECTIVE: Vestibular disorders and anxiety are closely related, probably because they share some neuronal pathways. Ageing and patient comorbidities are important facilitating factors, and multiple vascular risk factors could contribute to the onset of a vestibular syndrome called vascular vertigo. White matter lesions (WMLs) are often seen on magnetic resonance imaging (MRI) scans of elderly people and are related to various geriatric disorders, including dizziness. The cause of this correlation could be the disruption of neuronal networks that mediate higher vestibular cortical function...
July 2016: European Review for Medical and Pharmacological Sciences
Rik H G Olde Engberink, Hiddo J L Heerspink, Dick de Zeeuw, Liffert Vogt
AIMS: It has been suggested that sulodexide is able to lower blood pressure (BP). This may be attributed to its ability to restore the endothelial surface layer (ESL). As ESL perturbation is known to be related to the degree of kidney damage, we investigated whether albuminuria, reflecting ESL status, modified the BP-lowering potential of sulodexide. METHODS: A post hoc analysis of the double-blind, randomized, placebo-controlled sulodexide microalbuminuria (Sun-MICRO) and macroalbuminuria (Sun-MACRO) studies, including 1056 microalbuminuric and 843 macroalbuminuric subjects with type 2 diabetes receiving maximal tolerated renin-angiotensin-aldosterone system inhibitor therapy, was carried out...
July 14, 2016: British Journal of Clinical Pharmacology
Nizar Elleuch, Hichem Zidi, Zied Bellamine, Abdelaziz Hamdane, Mondher Guerchi, Nabil Jellazi
INTRODUCTION: Chronic venous disease (CVD) of the lower limbs is a common problem. It is more prevalent in women than in men and has a significant impact on patients' quality of life (QoL) and on the healthcare system. The aim of this study was to evaluate the efficacy of sulodexide in adult patients with CVD of the lower limbs and its effect on patients' QoL. METHODS: Patients with CVD were treated with sulodexide [250 LSU (lipasemic units) twice daily] for 3 months in a setting of real-life clinical practice...
September 2016: Advances in Therapy
Alejandro Gonzalez Ochoa
BACKGROUND: In the treatment of venous leg ulcers, vasoactive drugs such as diosmin hesperidin micronized purified flavonoids (DH), and recently sulodexide (SDX), have been used besides compression therapy and local measures. The purpose of this study is to investigate whether administering both drugs SDX and DH is better than DH alone in the treatment of venous ulcer. METHODS: In an open-label, observational, non-parallel trial, 70 patients with 90 venous ulcers were treated with multi-layer bandaging, local measures and DH, 37 patients (50 ulcers) also received SDX, 33 patients (40 ulcers) without SDX were the control group...
June 16, 2016: International Angiology: a Journal of the International Union of Angiology
Bin Wu, Jing Lu, Ming Yang, Ting Xu
BACKGROUND: Venous leg ulcers are common, chronic wounds caused by venous diseases, with a high recurrence rate and heavy disease burden. Compression therapy (bandages or stockings) is the first choice treatment for venous leg ulcers. However, when ulcers remain unhealed, medication can also be used with or without compression therapy. Sulodexide, a highly purified glycosaminoglycan (a naturally occurring molecule) has antithrombotic and profibrinolytic properties (it reduces the formation of blood clots) as well as anti-inflammatory effects...
2016: Cochrane Database of Systematic Reviews
Yang Yang, Lu Ma, Chao Wang, Deyang Kong, YaPing Wang, Changlin Mei
BACKGROUND: The activation of complement system is associated with the development of hepatitis B virus-associated membranous nephropathy (HBV-MN) and heparin could inhibit the activation of complement system. METHODS: This was a three-center trial. Seventy-nine patients with HBV-MN participated in the study. The follow-up of the study consisted of two periods: Stage 1 (S1) and Stage 2 (S2). All patients received 0.5mg entecavir plus 150-300mg/day of irbesartan but sulodexide was prescribed during S1...
July 2016: European Journal of Internal Medicine
Rik Hg Olde Engberink, Liffert Vogt
No abstract text is available yet for this article.
2016: Drug Design, Development and Therapy
Joost C van den Born, Anne-Roos S Frenay, Stephan J L Bakker, Andreas Pasch, Jan-Luuk Hillebrands, Hiddo J Lambers Heerspink, Harry van Goor
Diabetes is associated with a high incidence of microvascular disease, including nephropathy. Diabetic nephropathy is the most common cause of chronic kidney disease in the Western world. Sulfate in the urine is the metabolic end product of hydrogen sulfide (H2S), a recent discovered gaseous signaling molecule. Urinary sulfate has earlier shown beneficial predictive properties in renal transplant recipients. Based on the protective role of exogenous H2S in experimental models of diabetic nephropathy, we aimed to cross-sectionally investigate the association of sulfate with renal risk markers, and to prospectively investigate its predictive value for renal events in patients with diabetic nephropathy...
May 1, 2016: Nitric Oxide: Biology and Chemistry
Tomasz Urbanek, Zbigniew Krasinski, Katarzyna Sumińska-Jasińska, Ewa Baum, Grażyna Borej-Nowicka, Beata Begier-Krasińska, Andrzej Bręborowicz
BACKGROUND: According to previous studies, sulodexide suppresses intravascular inflammation when used in patients with chronic venous disease (CVD). In the current study, we tested the effect of prolonged in vitro exposure of human venous endothelial cells to the serum from patients with CVD, examining the function of these cells and how it is modified when these cells are simultaneously exposed to sulodexide. METHODS: Human umbilical venous cells (HUVEC) were cultured in standard medium (control), in medium supplemented with 5% serum pooled from CVD patients (CVD-serum) or in medium from CVD patients who were treated with sulodexide (CVD-serum-SUL)...
April 2016: International Angiology: a Journal of the International Union of Angiology
L Dobiaš, M Petrová, R Vojtko, O Uličná, O Vančová, V Kristová
This study investigates the effects of long-term treatment with sulodexide (SLX) on norepinephrine (NE)-induced contractions, acetylcholine(Ach)-induced relaxations, acute cyclooxygenase blockade by diclofenac (DIC) in isolated femoral arteries (FA) and the parameters of oxidative phosporylation in liver mitochondria. 15-weeks old Wistar rats were divided into four groups: control (C; injected with saline solution), treated control (C+SLX), diabetic (DM) and treated diabetic (DM+SLX). Diabetes was induced with a single i...
2015: Physiological Research
Evangelia Dounousi, Anila Duni, Konstantinos Leivaditis, Vasilios Vaios, Theodoros Eleftheriadis, Vassilios Liakopoulos
The burden of diabetes mellitus is relentlessly increasing. Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) worldwide and a major cause of morbidity and mortality in patients with diabetes. The current standard therapy of diabetic nephropathy involves intensive treatment of hyperglycemia and strict blood pressure control, mainly via blockade of the renin-angiotensin system (RAS). Attention has been drawn to additional beneficial effects of oral hypoglycemic drugs and fibrates on other aspects of diabetic nephropathy...
April 2015: Review of Diabetic Studies: RDS
Rui Li, Jing Xing, Xaojing Mu, Hui Wang, Lei Zhang, Yu Zhao, Yu Zhang
Sulodexide is a heterogeneous group of sulfated glycosaminoglycans (GAGs) that is mainly composed of low-molecular-weight heparin. Clinical studies have demonstrated that sulodexide is capable of reducing urinary albumin excretion rates in patients with type 1 and type 2 diabetes, suggesting that sulodexide has renal protection. However, this efficacy remains inconclusive. In this article, we used meta-analysis to summarize the clinical results of all prospective clinical studies in order to determine the clinical efficacy and safety of sulodexide in diabetic patients with nephropathy...
2015: Drug Design, Development and Therapy
Wenjun Yan, Baoqin Zhou, Yunfeng Shen, Gaosi Xu
With an increasing incidence, diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease and end-stage renal disease, and conventional therapies did not change this situation. This study intended to review and analyze the antioxidant and antithrombotic treatments of DKD for seeking novel therapeutic strategies. Relevant articles involved with antioxidant and antithrombotic treatments in DKD were retrieved and analyzed via systematic assessment. Meta-analysis showed that pancreatic kallikrein definitely reduced glycated hemoglobin in DKD patients (mean difference, 0...
November 2015: Iranian Journal of Kidney Diseases
Bożena Gabryel, Karolina Jarząbek, Grzegorz Machnik, Jakub Adamczyk, Dariusz Belowski, Ewa Obuchowicz, Tomasz Urbanek
Sulodexide (SDX) is widely used in the treatment of both arterial and venous thrombotic disorders. In addition to its recognized antithrombotic action, SDX has endothelial protective potential, which is independent of the coagulation/fibrinolysis system. However, the detailed molecular mechanisms of the endothelioprotective action of the drug are still unresolved. The aim of the present study was to determine whether treatment with SDX at concentrations of 0.125-0.5 lipase releasing unit (LRU)/ml have on the expression and activity of antioxidant enzymes in ischemic endothelial cells and how these effects might be related to the antiapoptotic properties of SDX...
January 2016: Microvascular Research
Irene Fernández Ruiz
No abstract text is available yet for this article.
December 2015: Nature Reviews. Cardiology
Giuseppe M Andreozzi, Angelo A Bignamini, Giovanni Davì, Gualtiero Palareti, Jiří Matuška, Martin Holý, Katarzyna Pawlaczyk-Gabriel, Andrej Džupina, German Y Sokurenko, Yury P Didenko, Laurentia D Andrei, Gianfranco Lessiani, Adriana Visonà
BACKGROUND: Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known. METHODS AND RESULTS: In this multicenter, double-blind study, 615 patients with first-ever unprovoked venous thromboembolism who had completed 3 to 12 months of oral anticoagulant treatment were randomly assigned to sulodexide 500 lipasemic units twice daily or placebo for 2 years, in addition to elastic stockings...
November 17, 2015: Circulation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"